Synthetic polyacrylate polymers as particulate intranasal vaccine delivery systems for the induction of mucosal immune response

Current Drug Delivery

Volumn 7, Issue 2, 2010, Pages 118-124

  Zaman, Mehfuz ^a   Simerska, Pavla ^a   Toth, Istvan ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Intranasal; Mucosal; Polyacrylate; Polymer; Vaccine

Indexed keywords

ALGINIC ACID; ANTIGEN; CARBOMER; CHITOSAN; CHOLERA TOXIN B SUBUNIT; CYTOKINE; HYALURONIC ACID; IMMUNOGLOBULIN A; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; LECTIN; LIPOSOME; MICROSPHERE; MUCIN; POLYACRYLIC ACID; POLYCARBOPHIL; POLYGLACTIN; POLYLACTIC ACID; POLYMER; STARCH; ULEX EUROPAEUS AGGLUTININ;

ADENOID; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; BIOCOMPATIBILITY; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL ADHESION; CELL DIFFERENTIATION; CELL INTERACTION; CERVICAL LYMPH NODE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RETENTION; DRUG SELF ADMINISTRATION; ENZYME DEGRADATION; EPITHELIUM CELL; IMMUNE RESPONSE; IN VIVO STUDY; LYMPHOID CELL; LYMPHOID TISSUE; MACROPHAGE; MUCOADHESION; MUCOCILIARY CLEARANCE; MUCOSAL IMMUNITY; NASOPHARYNX; NEISSERIA; NEISSERIA MENINGITIDIS; NONHUMAN; NOSE CAVITY; NOSE IRRITATION; PALATINE TONSIL; PARTICULATE MATTER; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; ULEX EUROPAEUS; VACCINATION; WALDEYER RING;

EID: 77950816448     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720110791011846     Document Type: Review

References (67)

1. Sharma, S.; Mukkur, T. K.; Benson, H. A.; Chen, Y. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J. Pharm. Sci., 2009, 98(3), 812-843.
2. Davis, S. S. Nasal vaccines. Adv. Drug Deliv. Rev., 2001, 51(1-3), 21-42.
3. Kiyono, H.; Fukuyama, S. NALT- versus Peyer's-patch-mediated mucosal immunity. Nat. Rev. Immunol., 2004, 4(9), 699-710. (Pubitemid 39223076)
4. Batzloff, M. R.; Hartas, J.; Zeng, W.; Jackson, D. C.; Good, M. F. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization. J. Infect. Dis., 2006, 194(3), 325-330.
5. Neutra, M. R.; Kozlowski, P. A. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol., 2006, 6(2), 148-158.
6. Slutter, B.; Hagenaars, N.; Jiskoot, W. Rational design of nasal vaccines. J. Drug Target, 2008, 16(1), 1-17.
7. Kallenius, G.; Pawlowski, A.; Brandtzaeg, P.; Svenson, S. Should a new tuberculosis vaccine be administered intranasally? Tuberculosis(Edinb), 2007, 87(4), 257-266. (Pubitemid 46936239)
8. Couch, R. B. Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. N. Engl. J. Med., 2004, 350(9), 860-861.
9. Wu, H. Y.; Nguyen, H. H.; Russell, M. W. Nasal lymphoid tissue(NALT) as a mucosal immune inductive site. Scand J. Immunol., 1997, 46(5), 506-513.
10. Csencsits, K. L.; Jutila, M. A.; Pascual, D. W. Mucosal addressin expression and binding-interactions with naive lymphocytes vary among the cranial, oral, and nasal-associated lymphoid tissues. Eur. J. Immunol., 2002, 32(11), 3029-3039.
11. Fujimura, Y. Evidence of M cells as portals of entry for antigens in the nasopharyngeal lymphoid tissue of humans. Virchows Arch., 2000, 436(6), 560-566. (Pubitemid 30406638)
12. Neutra, M. R. Current concepts in mucosal immunity. V Role of M cells in transepithelial transport of antigens and pathogens to the mucosal immune system. Am. J. Physiol., 1998, 274(5 Pt 1), G785-G791. (Pubitemid 28289505)
13. Man, A. L.; Prieto-Garcia, M. E.; Nicoletti, C. Improving M cell mediated transport across mucosal barriers: do certain bacteria hold the keys? Immunology, 2004, 113(1), 15-22. (Pubitemid 39178839)
14. van Ginkel, F. W.; Nguyen, H. H.; McGhee, J. R. Vaccines for mucosal immunity to combat emerging infectious diseases. Emerg. Infect. Dis., 2000, 6(2), 123-132.
15. Snoeck, V.; Peters, I. R.; Cox, E. The IgA system: a comparison of structure and function in different species. Vet. Res., 2006, 37(3), 455-467. (Pubitemid 43725031)
16. Illum, L. Nasal drug delivery - possibilities, problems and solutions. J. Control Release, 2003, 87(1-3), 187-198. (Pubitemid 36255456)
17. Alpar, H. O.; Somavarapu, S.; Atuah, K. N.; Bramwell, V. W. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv. Drug Deliv. Rev., 2005, 57(3), 411-430.
18. van der Lubben, I. M.; Verhoef, J. C.; Borchard, G.; Junginger, H. E. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur. J. Pharm. Sci., 2001, 14(3), 201-207. (Pubitemid 32884316)
19. Illum, L.; Jabbal-Gill, I.; Hinchcliffe, M.; Fisher, A. N.; Davis, S. S. Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Deliv. Rev., 2001, 51(1-3), 81-96. (Pubitemid 32763074)
20. Bramwell, V. W.; Perrie, Y. Particulate delivery systems for vaccines: what can we expect? J. Pharm. Pharmacol., 2006, 58(6), 717-728. (Pubitemid 43836159)
21. Corr, S. C.; Gahan, C. C.; Hill, C. M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis. FEMS Immunol. Med. Microbiol., 2008, 52(1), 2-12.
22. Man, A. L.; Prieto-Garcia, M. E.; Nicoletti, C. Improving M cell mediated transport across mucosal barriers: do certain bacteria hold the keys? Immunology, 2004, 113(1), 15-22. (Pubitemid 39178839)
23. Gebert, A. The role of M cells in the protection of mucosal membranes. Histochem. Cell Biol., 1997, 108(6), 455-470. (Pubitemid 28005213)
24. Clark, M. A.; Jepson, M. A.; Hirst, B. H. Exploiting M cells for drug and vaccine delivery. Adv. Drug Deliv. Rev., 2001, 50(1-2), 81-106.
25. Roth-Walter, F.; Scholl, I.; Untersmayr, E.; Ellinger, A.; Boltz-Nitulescu, G.; Scheiner, O.; Gabor, F.; Jensen-Jarolim, E. Mucosal targeting of allergen-loaded microspheres by Aleuria aurantia lectin. Vaccine, 2005, 23(21), 2703-2710. (Pubitemid 40381262)
26. Roth-Walter, F.; Scholl, I.; Untersmayr, E.; Fuchs, R.; Boltz-Nitulescu, G.; Weissenbock, A.; Scheiner, O.; Gabor, F.; Jensen-Jarolim, E. M cell targeting with Aleuria aurantia lectin as a novel approach for oral allergen immunotherapy. J. Allergy Clin. Immunol., 2004, 114(6), 1362-1368. (Pubitemid 39575891)
27. Gupta, P. N.; Khatri, K.; Goyal, A. K.; Mishra, N.; Vyas, S. P. M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J. Drug Target, 2007, 15(10), 701-713.
28. Gupta, P. N.; Mahor, S.; Rawat, A.; Khatri, K.; Goyal, A.; Vyas, S. P. Lectin anchored stabilized biodegradable nanoparticles for oral immunization 1. Development and in vitro evaluation. Int. J. Pharm., 2006, 318(1-2), 163-173.
29. Liang, M. T.; Davies, N. M.; Blanchfield, J. T.; Toth, I. Particulate systems as adjuvants and carriers for peptide and protein antigens. Curr. Drug Deliv., 2006, 3(4), 379-388. (Pubitemid 44534050)
30. Medina, E.; Guzman, C. A. Modulation of immune responses following antigen administration by mucosal route. FEMS Immunol. Med. Microbiol., 2000, 27(4), 305-311. (Pubitemid 30155825)
31. Csaba, N.; Garcia-Fuentes, M.; Alonso, M. J. Nanoparticles for nasal vaccination. Adv. Drug Deliv. Rev., 2009, 61(2), 140-157.
32. Rosenberg, A. S. Effects of protein aggregates: an immunologic perspective. AAPS J., 2006, 8(3), E501-E507.
33. Copland, M. J.; Rades, T.; Davies, N. M.; Baird, M. A. Lipid based particulate formulations for the delivery of antigen. Immunol. Cell Biol., 2005, 83(2), 97-105. (Pubitemid 40469317)
34. Sanders, M. T.; Brown, L. E.; Deliyannis, G.; Pearse, M. J. ISCOM-based vaccines: the second decade. Immunol. Cell Biol., 2005, 83(2), 119-128.
35. Pearse, M. J.; Drane, D. ISCOMATRIX adjuvant for antigen delivery. Adv. Drug Deliv. Rev., 2005, 57(3), 465-474.
36. Sjolander, A.; Cox, J. C.; Barr, I. G. ISCOMs: an adjuvant with multiple functions. J. Leukoc. Biol., 1998, 64(6), 713-723.
37. Jilek, S.; Merkle, H. P.; Walter, E. DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells. Adv. Drug Deliv. Rev., 2005, 57(3), 377-390. (Pubitemid 39550966)
38. Waeckerle-Men, Y.; Groettrup, M. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv. Drug Deliv. Rev., 2005, 57(3), 475-482. (Pubitemid 39550972)
39. Cui, C.; Stevens, V. C.; Schwendeman, S. P. Injectable polymer microspheres enhance immunogenicity of a contraceptive peptide vaccine. Vaccine, 2007, 25(3), 500-509.
40. Durrer, P.; Gluck, U.; Spyr, C.; Lang, A. B.; Zurbriggen, R.; Herzog, C.; Gluck, R. Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine, 2003, 21(27-30), 4328-4334. (Pubitemid 37130275)
41. Cusi, M. G.; Lomagistro, M. M.; Valassina, M.; Valensin, P. E.; Gluck, R. Immunopotentiating of mucosal and systemic antibody responses in mice by intranasal immunization with HLT-combined influenza virosomal vaccine. Vaccine, 2000, 18(25), 2838-2842. (Pubitemid 30254471)
42. Peek, L. J.; Middaugh, C. R.; Berkland, C. Nanotechnology in vaccine delivery. Adv. Drug Deliv. Rev., 2008, 60(8), 915-928.
43. Cyr, S. L.; Jones, T.; Stoica-Popescu, I.; Brewer, A.; Chabot, S.; Lussier, M.; Burt, D.; Ward, B. J. Intranasal proteosome-based respiratory syncytial virus(RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology. Vaccine, 2007, 25(29), 5378-5389.
44. Chabot, S. M.; Chernin, T. S.; Shawi, M.; Wagner, J.; Farrant, S.; Burt, D. S.; Cyr, S.; Neutra, M. R. TLR2 activation by proteosomes promotes uptake of particulate vaccines at mucosal surfaces. Vaccine, 2007, 25(29), 5348-5358.
45. Lowell, G. H.; Smith, L. F.; Seid, R. C.; Zollinger, W. D. Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants. J. Exp. Med., 1988, 167(2), 658-663.
46. Diamantstein, T.; Wagner, B.; Beyse, I.; Odenwald, M. V.; Schulz, G. Stimulation of humoral antibody formation by polyanions. I. The effect of polyacrylic acid on the primary immune response in mice immunized with sheep red blood cells. Eur. J. Immunol., 1971, 1(5), 335-340.
47. Lele, B. S.; Hoffman, A. S. Mucoadhesive drug carriers based on complexes of poly(acrylic acid) and PEGylated drugs having hydrolysable PEG-anhydride-drug linkages. J. Control Release, 2000, 69(2), 237-248.
48. Grabovac, V.; Guggi, D.; Bernkop-Schnurch, A. Comparison of the mucoadhesive properties of various polymers. Adv. Drug Deliv. Rev., 2005, 57(11), 1713-1723. (Pubitemid 41443475)
49. Takeuchi, H.; Yamamoto, H.; Kawashima, Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv. Drug Deliv. Rev., 2001, 47(1), 39-54. (Pubitemid 32209231)
50. Ugwoke, M. I.; Agu, R. U.; Verbeke, N.; Kinget, R. Nasal muco-adhesive drug delivery: background, applications, trends and future perspectives. Adv. Drug Deliv. Rev., 2005, 57(11), 1640-1665. (Pubitemid 41443473)
51. Coucke, D.; Schotsaert, M.; Libert, C.; Pringels, E.; Vervaet, C.; Foreman, P.; Saelens, X.; Remon, J. P. Spray-dried powders of starch and crosslinked poly(acrylic acid) as carriers for nasal delivery of inactivated influenza vaccine. Vaccine, 2009, 27(8), 1279-1286.
52. Turker, S.; Onur, E.; Ozer, Y. Nasal route and drug delivery systems. Pharm. World Sci., 2004, 26(3), 137-142. (Pubitemid 39012580)
53. Eguchi, M.; Ooya, T.; Yui, N. Controlling the mechanism of trypsin inhibition by the numbers of alpha-cyclodextrins and carboxyl groups in carboxyethylester-polyrotaxanes. J. Control Release, 2004, 96(2), 301-307. (Pubitemid 38481511)
54. Bai, J. P.; Chang, L. L.; Guo, J. H. Effects of polyacrylic polymers on the lumenal proteolysis of peptide drugs in the colon. J. Pharm. Sci., 1995, 84(11), 1291-1294.
55. Waksman, B. H. Adjuvants and Immune Regulation by Lymphoid Cells. Springer Semin. Immunopathol., 1979. 2, 5-33. (Pubitemid 10220609)
56. Schrader, J. W. Specific activation of the bone marrow-derived lymphocyte by antigen presented in a non-multivalent form. J. Exp. Med., 1973, 137(3), 844-849.
57. Mustafaev, M. Polyelectrolytes in immunology: fundamentals and perspectives. Tr. J. Chem., 1996. 20, 126-138.
58. Gall, D.; Knight, P. A. Hampson, F. Adjuvant activity of polyelectrolytes. Immunology, 1972, 23(4), 569-575.
59. Kabanov, V. A. From synthetic polyelectrolytes to polymer subunit vaccines. Pure Appl. Chem., 2004 76( 9), 1659-1677.
60. Kabanov, A. V. Polymer genomics: an insight into pharmacology and toxicology of nanomedicines. Adv. Drug Deliv. Rev., 2006, 58(15), 1597-1621. (Pubitemid 44841931)
61. Diamantstein, T.; Meinhold, H.; Wagner, B. Stimulation of humoral antibody formation by polyanions. V. Relationship between enhancement of sheep red blood cell uptake by the spleen and adjuvant action of dextran sulfate. Eur. J. Immunol., 1971, 1(6), 429-432.
62. Diamantstein, T.; Wagner, B.; Beyse, I.; Odenwald, M. V.; Schulz, G. Stimulation of humoral antibody formation by polyanions. II. The influence of sulfate esters of polymers on the immune response in mice. Eur. J. Immunol., 1971, 1(5), 340-343.
63. Diamantstein, T.; Wagner, B.; Odenwald, M. V.; Schulz, G. Stimulation of humoral antibody formation by polyanions. IV. The effects of dextran sulfate on the kinetics of secondary immune response in mice. Eur. J. Immunol. 1971, 1(6), 426-429.
64. Diamantstein, T.; Wagner, B.; L'Age-Stehr, J.; Beyse, I.; Odenwald, M. V.; Schultz, G. Stimulation of humoral antibody formation by polyanions. 3. Restoration of the immune response to sheep red blood cells by polyanions in thymectomized and lethally irradi ated mice protected with bone marrow cells. Eur. J. Immunol., 1971, 1(4), 302-304.
65. Cerutti, A. The regulation of IgA class switching. Nat. Rev. Immunol., 2008, 8(6), 421-434.
66. Flanary, S.; Hoffman, A. S.; Stayton, P. S. Antigen delivery with poly(propylacrylic acid) conjugation enhances MHC-1 presentation and T-cell activation. Bioconjug. Chem., 2009, 20(2), 241-248.
67. Hilgers, L. A.; Ghenne, L.; Nicolas, I.; Fochesato, M.; Lejeune, G.; Boon, B. Alkyl-polyacrylate esters are strong mucosal adjuvants. Vaccine, 2000, 18(28), 3319-13225. (Pubitemid 30408208)